Physician profile
Igor Janke
NPI 1861533366
$556.54
in general payments reported to CMS, 2019-2025
15 companies · $65.55 in 2025
The $65.55 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $277 · 2024: $214 · 2025: $65.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $108.22 | 2023-2024 | Azstarys, Azstarys |
| Tris Pharma INC | $92.24 | 2023-2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $58.41 | 2023-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.10 | 2023-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $38.50 | 2023-2024 | Jornay Pm |
| Lundbeck LLC | $38.43 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $24.67 | 2025 | Fanapt |
| Alkermes, INC. | $24.36 | 2023 | Aristada, Lybalvi |
| Bausch Health US, LLC | $22.16 | 2024 | Aplenzin |
| Tempus Ai, INC | $20.78 | 2024 | Tempus Pixel |
| Collegium Pharmaceutical, INC. | $20.35 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $18.29 | 2023 | Austedo Xr |
| Axsome Therapeutics, INC. | $16.17 | 2023 | Auvelity |
| Vertical Pharmaceuticals, LLC | $15.00 | 2024 | Relexxii |
| Harmony Biosciences LLC | $14.86 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Janke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.